,4 A phase 2a study evaluating the efficacy of oral dual JAK1/tyrosine kinase 2 inhibitor brepocitinib in cicatricial alopecias found significant downregulation of inflammatory biomarkers, including CCL5, and demonstrated a favorable safety profile.6 The gene discussed is CCL5; the disease is cicatricial alopecia.